The Women's Health Market Outlook to 2015

Find Industry reports, Company profiles
ReportLinker and Market Statistics

>> Get this Report Now by email!

The Women's Health Market Outlook to 2015
Published on December 2010

Report Summary

The global women's health market is increasingly competitive with, very few new active substances in the pipeline with the majority of
research activity focuses on development of 'me-too' products, combinations and advanced re-formulations. The Women's Health
Market Outlook to 2015 provides comprehensive coverage of the global women's health market, incorporating an overview of key
diseases specific to women and a detailed epidemiological analysis. It makes a wide-ranging analysis of both currently marketed
products and those in the product pipeline and gives an assessment of the leading players in the market.

Scope of this research
' Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive
market changes.
' Compare the franchises of the leading companies in global women's health market, and understand how the market share of these
companies will change.
' Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
' Identify the challenges confronted by leading players, and understand how recent events will impact the performance of leading
products.
' Access forecasts of the leading marketed and pipeline products through to 2015.

Research and analysis Highlights

The global women's health market was valued at $20.4bn at a Y-o-Y growth of 1%, the US dominated this market. Collectively, the
top five EU markets represented the second largest women's health market with 2009 sales of $3.5bn and a market share of 17.3%.

Hormonal contraceptives with 2009 sales of $9bn represented 44.3% of the market and remained the major therapeutic class in the
women's health market. Bayer's Yaz and Yasmin (drospirenone + ethinyl estradiol) were the largest selling drugs in this category
accounting for a market share of 24.3%.

The top 10 generic players in the global women's health market represented 68.3% of the total generic market in 2009. J&J followed
by Ferring remained the market leaders in the generic women's health market.

Key reasons to purchase this research
' What will be the major growth indications and the accompanying growth drivers in the women's health market over the next 6 years'
' Which companies led the the women's health market in 2009'
' Which products will be the future growth drivers for the women's health market'
' Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009'15'
' Which companies are best positioned to succeed in the women's health market over the period 2009'15'

The Women's Health Market Outlook to 2015 Page 1/8


Table of Content

Table of Contents
About the author 2
Disclaimer 2
Executive summary 12
Overview and epidemiology of women's health 12
Global market analysis 12
Pipeline analysis 13
Competitive landscape 14
Chapter 1 Overview and epidemiology of women's health 16
Summary 16
Introduction 17
Osteoporosis 17
Overview 17
Diagnosis treatment and management 18
Epidemiology 20
Forecast epidemiology 21
Hormonal contraception 22
Overview 22
Diagnosis treatment and management 22
Epidemiology 24
Common gynecological infections 26
Overview 26
Candidiasis 26
Bacterial vaginosis 27
Trichomoniasis 27
Diagnosis, treatment and management 27
Epidemiology 29
Hormone replacement therapies 34
Overview 34
Diagnosis, treatment and management 35
Chapter 2 Global market analysis 36
Summary 36
Market analysis by country 37
Market analysis by drug class 39
Key events in women's health market 44
Merck Serono sells women's health division to Teva 44
Gedeon Richter extends women's health franchise with PregLem acquisition 45
Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin 45
Elli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial 46
Leading brand dynamics 46
Evista (raloxifene) ' Eli Lilly 47
Yaz/Yasmin (drospirenone + ethinyl estradiol) ' Bayer 48
Premarin (conjugated estrogens) ' Pfizer 48
AndroGel (testosterone gel) ' Solvay 49



Nuvaring (ethinyl estradiol + etonogestrel) ' Merck & Co. 49
Mirena (levonorgestrel) ' Bayer 50
Gonal F (follitropin beta) ' Merck KGaA 50
Puregon (follitropin beta) ' Merck 50
Women's health generic market in the 7MM 51
Leading drug classes in the women's health generic market in the 7MM 52
Leading generic drugs in the in the women's health generic 7MM market 53
Global women's health sales forecast 55
Leading drugs sales forecast 56
Chapter 3 Pipeline analysis 57
Summary 57
Introduction 58
Women's health pipeline 58
Leading drugs in development 59
Profiles of key pipeline products 59
Prolia (denosumab) ' Amgen 59
Overview 59
Clinical 60
Natazia (estradiol valerate and dienogest) ' Bayer 61
Overview 61
Clinical 62
Viviant (bazedoxifene) ' Pfizer 62
Overview 62
Clinical 63
Elonva (corifollitropin alfa) ' Merck 64
Overview 64
Clinical 65
EllaOne (ulipristal acetate) ' HRA Pharma/Watson 66
Overview 66
Clinical 67
Nomac E2 (nomegestrol and estradiol) ' Merck & Co. 67
Overview 67
Clinical 68
Aprela (bazedoxifene and conjugated estrogen) ' Pfizer 68
Overview 68
Clinical 69
MK-0822 (odanacatib) ' Merck 70
Overview 70
Clinical 70
SMC021 (synthetic oral salmon calcitonin) ' Novartis 71
Overview 71
Clinical 71
Pipeline forecast of leading drugs in development 73
Chapter 4 Competitive landscape 74
Summary 74
Introduction 75
Sales performance of leading players 75
Bayer 76
Sales focus by drug class 76
Marketed product portfolio 77



Strategic and growth analysis 79
Drivers of growth 79
Resistors of growth 80
Merck & Co. 80
Pfizer 84
Teva 88
Solvay 92
Competitive positioning of the top 10 generic players in the 7MM women's heath market 95
Appendix 98
IMS data 98
Epidemiology forecast: 98
Market forecast: 99
Scope 99
Key women's health diseases covered in this report 100
Methodology 100
Glossary/Abbreviations 101

Table of figures
Figure 1: Typical treatment pattern in the treatment of osteoporosis 19
Figure 2: Global women's health market share by region, 2009 37
Figure 3: Competitive positioning of the women's health market by geography, 2009 39
Figure 4: Global hormonal contraceptives market share by formulations, 2009 41
Figure 5: Competitive dynamics of the top 10 brands in the global women's health market, 2009 51
Figure 6: The global women's health pipeline by stages of development, 2010 58
Figure 7: Key women's health drugs in late-stage development, December 2010 59



Figure 8: Competitive positioning of the top 10 players in the global women's health market, 2009 76
Figure 9: Bayer's women's health sales by drug class ($m), 2009 77
Figure 10: Merck &Co.'s women's health sales by drug class ($m), 2009 81
Figure 11: Pfizer's women's health sales by drug class ($m), 2009 85
Figure 12: Teva's women's health sales by drug class ($m), 2009 89
Figure 13: Solvay's women's health sales by drug class ($m), 2009 93
Figure 14: Competitive positioning of the top 10 generic players in the 7MM women's health market 97

Table of tables
Table 1: Estimated prevalence of hip fracture across the seven major markets, 2009 20
Table 2: Table 2: Forecast epidemiology of osteoporosis across the seven major markets, 2009'15 21
Table 3: Estimated prevalence of hormonal contraception use across the seven major markets, 2009 24
Table 4: Forecast use of contraceptives across the seven major markets, 2009'15 25
Table 5: Estimated prevalence of candidiasis across the seven major markets, 2009 29
Table 6: Estimated prevalence of trichomoniasis across the seven major markets, 2009 29
Table 7: Estimated prevalence of vaginosis across the seven major markets, 2009 30
Table 8: Forecast epidemiology of candidiasis across the seven major markets, 2009'15 31
Table 9: Forecast epidemiology of trichomoniasis across the seven major markets, 2009'15 32
Table 10: Forecast epidemiology of vaginosis across the seven major markets, 2009-15 33
Table 11: Global women's health market by geography ($m), 2009 38
Table 12: Leading therapeutic categories in global women's health market ($m), 2009 40
Table 13: Breakdown of the global hormonal contraceptive market by drug class ($m), 2009 41
Table 14: Leading hormonal contraceptive brands in the women's health market ($m), 2009 42
Table 15: Leading Gonadotropins brands, including other ovulation stimulants market ($m), 2009 43
Table 16: Leading brands in the estrogen market ($m), 2009 44
Table 17: Top 10 brands in the global women's health market ($m), 2009 47
Table 18: Women's health generic market in 7MM ($m), 2009 52
Table 19: Leading drug classes in the women's health generic 7MM market ($m), 2009 53
Table 20: Top 10 generic drugs in the 7MM women's health market ($m), 2009 54
Table 21: The global women's health market forecast ($m), 2009'15 55
Table 22: Leading brands sale forecast ($m), 2009'15 56
Table 23: An overview of Prolia 60
Table 24: An overview of Natazia 62
Table 25: An overview of Viviant 63
Table 26: An overview of Elonva 65
Table 27: An overview of EllaOne 66
Table 28: An overview of Nomac E2 68
Table 29: An overview of Aprela 69
Table 30: An overview of MK-0822 70
Table 31: An overview of SMC021 71
Table 32: Sales forecast for leading drugs in development ($m), 2009'15 73
Table 33: Top 10 players in the global women's health market ($m), 2009 75
Table 34: Bayer's top 10 marketed products in women's health ($m), 2009 78
Table 35: Bayer's late-stage pipeline in women's health, 2010 79
Table 36: Merck & Co.'s top 10 marketed products in women's health ($m), 2009 82
Table 37: Merck & Co's late-stage pipeline in women's health, 2010 83
Table 38: Pfizer's top 10 marketed products in women's health ($m), 2009 86
Table 39: Pfizer's late-stage pipeline in women's health, 2010 87
Table 40: Teva's top 10 marketed products in women's health ($m), 2009 90



Table 41: Teva's pipeline in women's health portfolio, 2010 91
Table 42: Solvay's top 10 marketed products in women's health ($m), 2009 94
Table 43: Top 10 generic players in the 7MM women's health market ($m), 2009 96



Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

The Women's Health Market Outlook to 2015

Product Formats
Please select the product formats and the quantity you require.

Digital Copy--USD 3 835.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________



Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


The Women's Health Market Outlook to 2015

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Recently uploaded

Recently uploaded (20)

The Women's Health Market Outlook to 2015